Literature DB >> 28409892

Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.

Sameer Sait1, Neeta Pandit-Taskar2, Shakeel Modak1.   

Abstract

123 I-meta-iodo benzyl guanidine (MIBG) scans are considered the gold standard imaging in neuroblastoma; however, flouro deoxy glucose positron emission tomography (FDG-PET) scans have increased sensitivity in adults with pheochromocytoma/paraganglioma. We describe a pediatric patient initially considered to have localized neuroblastoma based on anatomical imaging and 123 I-MIBG scan, but subsequent investigations revealed germline succinate dehydrogenase complex iron sulfur subunit B (SDHB) mutation-associated pheochromocytoma with multiple FDG-avid skeletal metastases. We then compared 123 I-MIBG and FDG-PET scans in children with metastatic pheochromocytoma/paraganglioma. FDG-PET was superior to 123 I-MIBG scan for the detection of skeletal metastases (median number of skeletal lesions detected 10 [range 1-30] vs. 2 [range 1-26], respectively; P = 0.005 by t-test). FDG-PET should be considered the functional scan of choice in children with pheochromocytoma/paraganglioma.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  imaging; metastatic pheochromocytoma; solid tumor

Mesh:

Substances:

Year:  2017        PMID: 28409892     DOI: 10.1002/pbc.26549

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.

Authors:  Jonathan Metts; Brittany Harrington; Emad Salman; Scott M Bradfield; Jennifer Flanary; Maua Mosha; Ernest Amankwah; Stacie Stapleton
Journal:  Childs Nerv Syst       Date:  2022-03-08       Impact factor: 1.475

2.  Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.

Authors:  Guangrong Lu; Ping Zhu; Mayank Rao; Nadine Linendoll; L Maximilian Buja; Meenakshi B Bhattacharjee; Robert E Brown; Leomar Y Ballester; Xuejun Tian; Monika Pilichowska; Julian K Wu; Georgene W Hergenroeder; Williams F Glass; Lei Chen; Rongzhen Zhang; Anil K Pillai; Robert L Hunter; Jay-Jiguang Zhu
Journal:  J Neurooncol       Date:  2022-10-06       Impact factor: 4.506

Review 3.  Clinical Practice Guidance: Surveillance for phaeochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers.

Authors:  Mei Yin Wong; Katrina A Andrews; Benjamin G Challis; Soo-Mi Park; Carlo L Acerini; Eamonn R Maher; Ruth T Casey
Journal:  Clin Endocrinol (Oxf)       Date:  2019-01-29       Impact factor: 3.478

4.  Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion.

Authors:  Minghao Li; Christina Pamporaki; Stephanie M J Fliedner; Henri J L M Timmers; Svenja Nölting; Felix Beuschlein; Aleksander Prejbisz; Hanna Remde; Mercedes Robledo; Stefan R Bornstein; Jacques W M Lenders; Graeme Eisenhofer; Nicole Bechmann
Journal:  Discov Oncol       Date:  2021-03-19

5.  The Utility of 68Ga-DOTATATE PET/CT in Localizing Primary/Metastatic Pheochromocytoma and Paraganglioma: Asian Indian Experience.

Authors:  Sanjeet Kumar Jaiswal; Vijaya Sarathi; Gaurav Malhotra; Priyanka Verma; Priya Hira; Padma Badhe; Saba Samad Memon; Rohit Barnabas; Virendra A Patil; R Lila; Nalini S Shah; Tushar Bandgar
Journal:  Indian J Endocrinol Metab       Date:  2022-01-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.